CCCC
C4 Therapeutics Inc
NASDAQ: CCCC · HEALTHCARE · BIOTECHNOLOGY
$2.83
+10.55% today
Updated 2026-04-30
Market cap
$281.02M
P/E ratio
—
P/S ratio
7.82x
EPS (TTM)
$-1.27
Dividend yield
—
52W range
$1 – $4
Volume
3.0M
C4 Therapeutics Inc (CCCC) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.36M | $21.38M | $33.20M | $45.78M | $31.10M | $20.76M | $35.58M | $35.95M |
| Revenue growth (YoY) | — | +10.4% | +55.3% | +37.9% | -32.1% | -33.3% | +71.4% | +1.0% |
| Cost of revenue | $28.59M | $47.66M | $78.44M | $2.91M | $7.57M | $7.74M | $7.89M | $7.97M |
| Gross profit | $-9.23M | $21.38M | $-45.24M | $45.78M | $31.10M | $13.02M | $35.58M | $27.97M |
| Gross margin | -47.7% | 100.0% | -136.3% | 100.0% | 100.0% | 62.7% | 100.0% | 77.8% |
| R&D | $28.59M | $48.06M | $78.44M | $94.67M | $117.84M | $117.71M | $110.64M | $104.24M |
| SG&A | $7.16M | $8.77M | $15.20M | $33.25M | $42.79M | $42.08M | $42.12M | $36.20M |
| Operating income | $-16.39M | $-35.45M | $-60.45M | $-82.13M | $-129.53M | $-139.03M | $-119.61M | $-104.49M |
| Operating margin | -84.6% | -165.8% | -182.1% | -179.4% | -416.6% | -669.8% | -336.1% | -290.7% |
| EBITDA | $-15.12M | $-31.70M | $-58.83M | $-80.25M | $-124.28M | $-122.10M | $-103.37M | $-102.91M |
| EBITDA margin | -78.1% | -148.3% | -177.2% | -175.3% | -399.7% | -588.3% | -290.5% | -286.3% |
| EBIT | $-18.69M | $-33.30M | $-60.45M | $-81.75M | $-125.96M | $-129.84M | $-105.19M | $-104.87M |
| Interest expense | $0.00 | $2.16M | $1.23M | $2.15M | $2.22M | $1.37M | $0.00 | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-15.71M | $-34.10M | $-66.33M | $-83.89M | $-128.18M | $-132.49M | $-105.32M | $-104.99M |
| Net income growth (YoY) | — | -117.0% | -94.5% | -26.5% | -52.8% | -3.4% | +20.5% | +0.3% |
| Profit margin | -81.1% | -159.5% | -199.8% | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |